|
1
|
CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion.
|
Cell
|
2002
|
2.77
|
|
2
|
The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity.
|
J Biol Chem
|
2003
|
2.02
|
|
3
|
Ubiquitin-independent degradation of proteins by the proteasome.
|
Biochim Biophys Acta
|
2008
|
1.69
|
|
4
|
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.
|
Mol Cell Biol
|
2005
|
1.55
|
|
5
|
SUMO under stress.
|
Biochem Soc Trans
|
2008
|
1.47
|
|
6
|
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1.
|
J Cell Biol
|
2004
|
1.24
|
|
7
|
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.
|
Mol Cell Biol
|
2007
|
1.16
|
|
8
|
c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo.
|
Mol Cell Biol
|
2003
|
1.06
|
|
9
|
The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression.
|
Oncogene
|
2003
|
1.04
|
|
10
|
SUMOylation regulates the transcriptional activity of JunB in T lymphocytes.
|
J Immunol
|
2008
|
1.03
|
|
11
|
Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic.
|
J Biol Chem
|
2007
|
0.99
|
|
12
|
Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution.
|
J Biol Chem
|
2010
|
0.96
|
|
13
|
Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells.
|
Virology
|
2005
|
0.96
|
|
14
|
JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.
|
Mol Cell Biol
|
2008
|
0.93
|
|
15
|
A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.
|
PLoS Pathog
|
2010
|
0.92
|
|
16
|
A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking.
|
Mol Biol Cell
|
2008
|
0.91
|
|
17
|
Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?
|
Biochimie
|
2007
|
0.91
|
|
18
|
Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector.
|
Virology
|
2002
|
0.84
|
|
19
|
An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells.
|
PLoS One
|
2010
|
0.84
|
|
20
|
High in vivo production of a model monoclonal antibody on adenoviral gene transfer.
|
Hum Gene Ther
|
2002
|
0.84
|
|
21
|
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation.
|
Genet Vaccines Ther
|
2004
|
0.82
|
|
22
|
Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.
|
Blood
|
2012
|
0.82
|
|
23
|
Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
|
J Virol
|
2005
|
0.82
|
|
24
|
Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor.
|
J Virol
|
2003
|
0.81
|
|
25
|
Multiple degradation pathways for Fos family proteins.
|
Ann N Y Acad Sci
|
2002
|
0.80
|
|
26
|
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.
|
J Virol
|
2010
|
0.80
|
|
27
|
Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.
|
J Virol
|
2007
|
0.80
|
|
28
|
Fos family protein degradation by the proteasome.
|
Biochem Soc Trans
|
2008
|
0.80
|
|
29
|
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?
|
Crit Rev Oncol Hematol
|
2005
|
0.79
|
|
30
|
The effects of N-terminal insertion into VSV-G of an scFv peptide.
|
Virol J
|
2006
|
0.79
|
|
31
|
Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy.
|
J Virol
|
2006
|
0.79
|
|
32
|
The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells.
|
Virus Res
|
2002
|
0.79
|
|
33
|
In vivo infection of mice by replication-competent MLV-based retroviral vectors.
|
Methods Mol Med
|
2003
|
0.78
|
|
34
|
Skin as a potential organ for ectopic monoclonal antibody production.
|
J Invest Dermatol
|
2002
|
0.78
|
|
35
|
Monoclonal antibody-based genetic immunotherapy.
|
Curr Gene Ther
|
2004
|
0.77
|
|
36
|
Chromatin loop organization of the junb locus in mouse dendritic cells.
|
Nucleic Acids Res
|
2013
|
0.76
|
|
37
|
Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses.
|
Biochem Pharmacol
|
2002
|
0.75
|
|
38
|
[Proteasomal degradation: from addressing of substrates to therapeutical perspectives].
|
Med Sci (Paris)
|
2005
|
0.75
|
|
39
|
[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?].
|
Med Sci (Paris)
|
2013
|
0.75
|